The DRX-Rise Mobile X-ray System reportedly combines optimal image quality with enhanced maneuverability and ease of use for radiologists.
With the promise of artificial intelligence (AI)-powered image processing and features that promote workflow productivity and maneuverability, Carestream Health has launched the DRX-Rise Mobile X-ray System.
One of the features of the DRX-Rise Mobile X-ray System is Carestream Health’s AI-propelled ImageView Software, which facilitates image quality and dosing efficiency through robust image processing, according to Carestream Health.
The company said other attributes of the new X-ray system include in-bin detector charging, two touchscreen displays and new drive capabilities that help ensure optimal maneuverability and positioning at a patient’s bedside.
“The DRX-Rise Mobile X-ray System delivers high-end features that support the most critical needs in medical imaging: exceptional image quality for confident diagnosis; workflow-accelerating attributes for productivity; and a more comfortable imaging experience for patients – all without significantly impacting capital budget,” noted Jordan Berry, the global marketing manager for Carestream Health.
(Editor’s note: For related content, see “Autonomous AI Shows Nearly 27 Percent Higher Sensitivity than Radiology Reports for Abnormal Chest X-Rays” and “Canon Medical Launches New CT and X-Ray Modalities at ECR 2023.”)
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.